Natori Daisuke, Ozasa Hiroaki, Shima Yusuke, Mizumoto Chisaki, Suminaga Keiichiro, Nomizo Takashi, Ajimizu Hitomi, Yoshida Hironori, Hirai Toyohiro
Department of Respiratory Medicine, Graduate School of Medicine, Kyoto University, Kyoto 606-8507, Japan.
Department of Hematology and Oncology, Graduate School of Medicine, Kyoto University, Kyoto 606-8507, Japan.
Mol Clin Oncol. 2024 Feb 23;20(4):33. doi: 10.3892/mco.2024.2731. eCollection 2024 Apr.
The combined occurrence of lung cancer and B-cell lymphoma, such as mucosa-associated lymphoid tissue (MALT) lymphoma, is rare. The efficacy and safety of immune checkpoint inhibitors (ICIs) remain unknown in this population of patients, and the occurrence of ICI-induced exacerbation of lymphoma is concerning. The present study describes a case of successful treatment with pembrolizumab following rituximab-containing chemotherapy for lung cancer complicated by MALT lymphoma. The patient was a 69-year-old woman diagnosed with MALT lymphoma based on a biopsy of stomach ulcerative lesions, and advanced lung cancer based on a biopsy of a lymph node in the left pulmonary hilum. Complete remission was achieved after one cycle of rituximab and bendamustine therapy for MALT lymphoma. Pembrolizumab monotherapy was subsequently initiated, resulting in a good response for lung cancer without recurrence or exacerbation of the lymphoma. In conclusion, the present study suggested that pembrolizumab, following rituximab-containing therapy, could be a treatment option for patients with lung cancer coexisting with MALT lymphoma.
肺癌与B细胞淋巴瘤（如黏膜相关淋巴组织（MALT）淋巴瘤）的合并发生情况较为罕见。免疫检查点抑制剂（ICI）在这类患者群体中的疗效和安全性尚不清楚，且ICI诱发淋巴瘤病情加重的情况令人担忧。本研究描述了1例在含利妥昔单抗的化疗后接受帕博利珠单抗成功治疗的病例，该患者为肺癌合并MALT淋巴瘤。患者为一名69岁女性，基于胃溃疡性病变活检诊断为MALT淋巴瘤，基于左肺门淋巴结活检诊断为晚期肺癌。MALT淋巴瘤经一个周期的利妥昔单抗和苯达莫司汀治疗后达到完全缓解。随后开始帕博利珠单抗单药治疗，对肺癌产生了良好反应，且淋巴瘤未复发或加重。总之，本研究表明，在含利妥昔单抗的治疗后，帕博利珠单抗可能是肺癌合并MALT淋巴瘤患者的一种治疗选择。
